Klegerman Rhythmia Medical’s innovative mapping technology is likely to significantly enhance doctor treatment options and eventually facilitate and improve what today are lengthy and complicated methods, stated Doron Harlev, co-founder and co-chief executive officer of Rhythmia Medical. After the U clears the mapping program.S. Drug and Meals Administration and receives CE Tag approval in European countries, Boston Scientific expects to begin with a limited market release of the machine in 2013 and complete market launch in 2014..Contrary to what Patrick Sullivan, Ph.D, of the University of Colorado College of Pharmacy, and colleagues expected, patients did not turn to other prescription drugs for allergies and asthma or even to antibiotics in higher amounts after loratadine lost its prescription-only status. This class of drugs also includes cetirizine and fexofenadine . The medications treat seasonal allergy symptoms and chronic nasal congestion without a few of the side effects, such as drowsiness, of early antihistamines.